

## **IN THE CLAIMS:**

Claims 1-11 (canceled).

Claim 12 (currently amended): Biodegradable, ~~monolithic plastic~~ viscous antitumor composition with prolonged release of an antitumor agent for administration into tissues, comprising: at least one antitumor agent being homogeneously distributed in ~~[[and]]~~ a carrier, consisting of biodegradable oligoester, having the numeric mean relative molecular mass  $M_n$  from 650 to 7,500, the mass mean relative molecular mass  $M_w$  from 800 to 10,000 and the glass transition temperature  $T_g$  from  $-35$  to  $45^\circ \text{C}$ , and which is prepared by polycondensation reaction of polyhydric alcohol containing at least 3 hydroxy groups with at least one aliphatic  $\alpha$ -hydroxy acid in the molar ratio of polyhydric alcohol to aliphatic  $\alpha$ -hydroxy acid being from 0.5:99.5 to 12:88, wherein the essential molecule of biodegradable oligoester is a polyhydric alcohol, to the hydroxy groups of which chains created from several molecules of at least one aliphatic  $\alpha$ -hydroxy acid are bound by ester bonds, and being ~~in that it is~~ in the form of homogenous one-phase solution, micellar colloid system, one-phase or two-phase gel, suspension, paste or emulsion.

Claim 13 (previously presented): The composition according to Claim 12, further comprising at least one liquid biocompatible plasticizer, wherein the weight ratio of at least one biocompatible plasticizer to biodegradable oligoester is from 1:20 to 9:10.

Claim 14 (previously presented): The composition according to Claim 13, wherein the liquid biocompatible plasticizer is soluble in the carrier and imperfectly soluble or

insoluble in water.

Claim 15 (previously presented): The composition according to Claim 12, further comprising at least one agent influencing the kinetics of the release of the antitumor agent.

Claim 16 (previously presented): The composition according to Claim 12, further comprising at least one stabilizer of the antitumor agent or carrier.

Claim 17 (previously presented): The preparation of the antitumor composition according to Claim 12, wherein an antitumor agent, a carrier, and optionally a liquid biocompatible plasticizer, an agent influencing the kinetics of the release of the antitumor agent, a stabilizer of the antitumor agent or a stabilizer of the carrier are heated to the temperature of 35 to 75° C and mixed.